CHEK Stock Forecast 2025-2026
Distance to CHEK Price Targets
CHEK Price Momentum
🤔 Considering Check Cap (CHEK)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest CHEK Stock Price Targets & Analyst Predictions
CHEK has shown a year-to-date change of -22.2% and a 1-year change of -59.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CHEK. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHEK Analyst Ratings
CHEK Price Target Range
Latest CHEK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHEK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 7, 2023 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $0.00 |
| May 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $7.00 |
| Apr 5, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $7.00 |
| Aug 9, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $3.00 |
| Mar 17, 2021 | Dawson James | Neutral | Downgrade | $0.00 | |
| Mar 16, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $4.00 |
| Nov 19, 2020 | HC Wainwright & Co. | Buy | Maintains | $1.50 | |
| Apr 24, 2020 | HC Wainwright & Co. | Buy | Reiterates | $2.00 | |
| Apr 24, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Feb 5, 2019 | Dougherty | Buy | Initiates | $0.00 | |
| Feb 5, 2019 | Dougherty & Co. | Buy | Initiates | $0.00 | |
| May 23, 2018 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| May 23, 2018 | H.C. Wainwright | Buy | Maintains | $0.00 | |
| Mar 16, 2016 | Chardan Capital | Buy | Maintains | $6.00 | |
| Oct 8, 2015 | Maxim Group | Buy | Initiates | $0.00 |
Check-Cap Ltd. (CHEK) Competitors
The following stocks are similar to Check Cap based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Check-Cap Ltd. (CHEK) Financial Data
Check-Cap Ltd. has a market capitalization of $4.51M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -53.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Check-Cap Ltd. (CHEK) Business Model
About Check-Cap Ltd.
Develops innovative colorectal cancer screening solutions.
The company generates revenue by offering its advanced capsule-based screening platform, which enhances early detection of colorectal cancer without requiring bowel preparation. This patient-friendly method aims to increase screening participation rates, thereby potentially reducing healthcare costs associated with late-stage cancer diagnoses.
Check-Cap's technology is non-invasive and radiation-free, making it appealing to both healthcare providers and regulators. The company's focus on preventive care positions it as a significant player in the healthcare industry, addressing a critical health concern globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
85
CEO
Mr. Alex Ovadia
Country
Israel
IPO Year
2015
Website
www.check-cap.comCheck-Cap Ltd. (CHEK) Latest News & Analysis
Why Is Check-Cap (CHEK) Stock Up 44% Today?
11 months agoCheck-Cap (NASDAQ: CHEK) stock is rising following the announcement of a business combination with Nobul AI, which will take over leadership and ownership of the company.
The rise in Check-Cap's stock reflects investor optimism about the business combination with Nobul AI, which could lead to strategic growth and enhanced market position.
Nobul AI Corp. and Check-Cap Ltd. plan a business combination to form an AI-driven fintech marketplace, with intentions to list on Nasdaq and TSX.
The business combination signals potential growth in the AI fintech sector, attracting investor interest and possibly enhancing stock value with dual listings on Nasdaq and TSX.
Symetryx Corporation announced that shareholders of Check-Cap Ltd. (NASDAQ: CHEK) approved all director nominees proposed by Symetryx at the AGM on December 18, 2023.
The election of Symetryx's director nominees at Check-Cap could signal a change in strategy or management, potentially impacting future performance and stock value.
Symetryx advises Check-Cap Ltd. shareholders to vote against the Keystone Dental merger and support their independent board nominees by the December 14, 2023 deadline.
Shareholder votes on the Keystone Dental merger and board nominees can significantly impact Check-Cap's governance and strategic direction, influencing stock performance and investor sentiment.
Symetryx is urging Check-Cap Ltd. shareholders to vote against the Keystone Dental and support its slate of independent director nominees.
Symetryx's push for shareholder support against Keystone Dental and for its director nominees signals potential shifts in governance and strategy at Check-Cap, impacting future performance and investor sentiment.
Symetryx Corporation urges Check-Cap Ltd. shareholders to review an open letter from Dr. Yoav Kimchy, highlighting concerns over the undervaluation of Check-Cap's intellectual property in the Keystone Dental deal.
Concerns over the undervaluation of Check-Cap's intellectual property could lead to shareholder unrest and impact stock performance, influencing investment decisions.
Frequently Asked Questions About CHEK Stock
What is Check-Cap Ltd.'s (CHEK) stock forecast for 2025?
Analyst forecasts for Check-Cap Ltd. (CHEK) are not currently available. The stock is trading at $0.77.
Is CHEK stock a good investment in 2025?
According to current analyst ratings, CHEK has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHEK stock?
Price predictions from Wall Street analysts for CHEK are not currently available. The stock is trading at $0.77.
What is Check-Cap Ltd.'s business model?
The company generates revenue by offering its advanced capsule-based screening platform, which enhances early detection of colorectal cancer without requiring bowel preparation. This patient-friendly method aims to increase screening participation rates, thereby potentially reducing healthcare costs associated with late-stage cancer diagnoses.
What is the highest forecasted price for CHEK Check-Cap Ltd.?
Price targets from Wall Street analysts for CHEK are not currently available. The stock is trading at $0.77.
What is the lowest forecasted price for CHEK Check-Cap Ltd.?
Price targets from Wall Street analysts for CHEK are not currently available. The stock is trading at $0.77.
What is the overall CHEK consensus from analysts for Check-Cap Ltd.?
The overall analyst consensus for CHEK is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are CHEK stock price projections?
Stock price projections, including those for Check-Cap Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
